A routine visit to his Allergist led Scott to recognize his increased risk for esophageal precancer. Scott shares his story and what he wants everyone to know about this preventable disease. See his full story here: https://lnkd.in/g76J77gU #EsoGuard #EarlyDetectionSavesLives
Lucid Diagnostics
Medical Equipment Manufacturing
New York, NY 6,448 followers
Lucid Diagnostics is an esophageal cancer prevention medical diagnostics company. Nasdaq: LUCD
About us
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.
- Website
-
http://www.LucidDx.com
External link for Lucid Diagnostics
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
one grand central place
Suite 4600
New York, NY 10165 , US
Employees at Lucid Diagnostics
-
Jim Fricchione
ESOPHAGEAL CANCER IS PREVENTABLE
-
Joe Erfort
-
Suman Verma
Chief Scientific Officer (CSO), Lucid Diagnostics (Nasdaq: LUCD), VP of Molecular Diagnostics, PAVmed Inc. (Nasdaq: PAVM)
-
Shaun O'Neil
President & Chief Operating Officer at Lucid Diagnostics | (Nasdaq: LUCD) and EVP & Chief Operating Officer at PAVmed Inc. | (Nasdaq: PAVM)
Updates
-
We're thrilled to announce the launch of our new corporate website, https://www.luciddx.com/ "We designed the new website to highlight our mission to prevent esophageal cancer and offer patients, healthcare professionals, investors, and other interested parties a user-friendly experience with easily accessible, informative content on Lucid and its innovative technologies," said Jenna Mowatt, Vice President of Marketing and Communications at Lucid Diagnostics. "We sought to elevate our brand through modern design and comprehensive content reflecting our team's rigorous data-driven approach and trailblazing spirit." Read more: https://lnkd.in/giKg-fhB
-
"We are grateful to Dr. Nick Shaheen and his co-investigators for this valuable contribution to the clinical evidence supporting EsoGuard esophageal precancer testing," said Victoria T. Lee, M.D., Lucid's Chief Medical Officer. "This second multi-center clinical validation study in an intended use screening population demonstrates nearly identical EsoGuard performance compared to two previously reported National Cancer Institute (NCI)-funded case-control studies—a multi-center pivotal study published in Science Translational Medicine introducing the technology and a multi-center study from the BETRNet consortium recently published in the American Journal of Gastroenterology. Additionally, the previously announced and now peer-reviewed results of the Cleveland VA screening study demonstrated an identical NPV, and a similar sensitivity of 92.9%. Collectively, these four clinical validity studies demonstrate an unprecedented performance of a molecular diagnostic test in detecting a precancer. They strongly support EsoGuard's use as a widespread screening tool to prevent esophageal cancer through the early detection of esophageal precancer." Read more here: https://lnkd.in/gDGYqnJD #EarlyDetection #CancerPrevention
-
We're #hiring a new Clinical Laboratory Assistant in Lake Forest, California. Apply today or share this post with your network.
-
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF "There is a startling number of firefighters being diagnosed with and dying from esophageal cancer, and the EsoGuard test from Lucid Diagnostics is able to detect precancer signals and allow firefighters like me to go through treatment before actually developing cancer. I strongly encourage all firefighters to take advantage of the #CheckYourFoodTube esophageal precancer screening events, as I did." said Sam Dillon, Boston Firefighters Local 718 IAFF President Read more here: https://lnkd.in/gCankGEf #Firefighter #EarlyDetection
-
+4
-
Victoria T. Lee joined Ron E. Peck of the The Phia Group, LLC to discuss the second most lethal cancer in the U.S. and the first-of-its-kind test enabling detection of the precancerous condition. Learn how you can offer this #earlydetection test as a benefit for your team. Listen here: https://lnkd.in/gFSd6Ywc #Healthcare #CheckYourFoodTube
-
We're proud to partner with Anderson County, SC firefighters in their fight to prevent esophageal cancer. This week, they offered their team precancer screenings with the EsoGuard test. With a 62% higher risk, early detection is crucial for these heroes. "Screening is like fire prevention," said Honea Path Fire Chief, Jimmy Smith, MD This screening isn’t limited to firefighters. Doctors advise that individuals with risk factors, including family history, should also consider getting screened. #EarlyDetection #HealthTech https://lnkd.in/gQj7mgCS
-
Lucid Diagnostics reposted this
Board member Juliana Elstad enjoys a moment with Lishan Aklog, MD who leads our Board committee on health equity, and Tracy MacNeal, who leads our Board subcommittee on women’s health equity, at our standing-room-only Medtech Showcase on Capitol Hill yesterday evening. Featuring 44 AdvaMed member companies large and small, the event gave Members of Congress and over 200 congressional staff a firsthand look at the #AI-driven #medtech that is transforming patient care and promoting health equity around the world. #medtechshowcase
-
Join Shaun O'Neil and Lishan Aklog, MD tomorrow at AdvaMed's Medtech Showcase and Reception as they share the technology behind the only commercially available test for detection of esophageal precancer. Register here: https://lnkd.in/e-2esCUQ #medtechshowcase #EsoGuard
-
"I'm here for a reason, so I can tell my story. If I don't do anything more, than help one patient avoid esophageal cancer, I will have done my job." Don Martin, Esophageal Cancer Survivor This #NationalCancerSurvivorMonth we celebrate Don and all those impacted by cancer. Your strength, resilience, and hope are remarkable. #CelebrateSurvivorship